Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer

Published:2018-08-03 Issue: Volume:9 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Manjarrez-Orduño Nataly,Menard Laurence C.,Kansal Selena,Fischer Paul,Kakrecha Bijal,Jiang Can,Cunningham Mark,Greenawalt Danielle,Patel Vishal,Yang Minghui,Golhar Ryan,Carman Julie A.,Lezhnin Sergey,Dai Hongyue,Kayne Paul S.,Suchard Suzanne J.,Bernstein Steven H.,Nadler Steven G.

Funder

Bristol-Myers Squibb

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference30 articles.

1. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial;Hodi;Lancet Oncol,2016

2. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial;Hui;Ann Oncol,2017

3. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination;Boutros;Nat Rev Clin Oncol,2016

4. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients;Herbst;Nature,2014

5. Genetic basis for clinical response to CTLA-4 blockade in melanoma;Snyder;N Engl J Med,2014

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist’s Perspective on Current Knowledge;International Journal of Molecular Sciences;2024-08-31

2. Yttrium-90 Induces an Effector Memory Response with Neoantigen Clonotype Expansion: Implications for Immunotherapy;Cancer Research Communications;2024-08-01

3. A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients;Cancers;2024-07-11

4. Peripheral Blood Biomarkers Predicting the Efficacy of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Retrospective Study;2024-07-02

5. Soluble CD26: From Suggested Biomarker for Cancer Diagnosis to Plausible Marker for Dynamic Monitoring of Immunotherapy;Cancers;2024-06-30